Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132773 | 0.91 | ALDH1A1 (0.78) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL16327379 | 0.91 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP4F2CYP4A11KMT2A | |
| E1501 SCHEMBL6403243 | 0.90 | ALDH1A1 (0.85) | ALDH1A1CYP3A4KMT2AHPGDSMN1; SMN2 | |
| E1501 SCHEMBL8527328 | 0.88 | ALDH1A1 (0.81) | ALDH1A1CYP3A4KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL126492 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL4198688 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL11315920 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL10604973 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL10996267 | 0.83 | CYP3A4 (0.53) | ALDH1A1CYP3A4CYP4F2CYP4A11PPARG | |
| SCHEMBL10017478 | 0.83 | ALDH1A1 (0.67) | ALDH1A1CYP3A4KMT2AMEN1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802139-B2 | Pharmaceutical composition and the use thereof in the treatment of autoimmune diseases | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-10-31 | — | — | US | disclosed |
| CN-107567445-B | 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity | 坎塞拉有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2018-05-03 | — | — | US | disclosed |
| WO-2014168772-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014168771-A2 | ANTIMICROBIAL CATIONIC POLYCARBONATES | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-10-16 | — | — | WO | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7232817-B2 | α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7202258-B2 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-6600080-B1 | Method of alcohols such as cyclohexanedimethanol, a benzyl ester is obtained, for example, by the reaction between a benzyl compound and carboxylic acid in the presence of oxygen and a catalyst including palladium, gold ultra fine particles | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1090902-A2 | Method for producing alcohols such as cyclohexanedimethanol | Nippon Shokubai Co., Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-3993699-A | IN AROMATIC SOLVENT | HODOGAYA CHEMICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802139-B2 | Pharmaceutical composition and the use thereof in the treatment of autoimmune diseases | QPCTL, QARS1, QPCT | ALDH1A1 1297/4885CYP3A4 2841/4885CYP4F2 985/4885 |
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | VDR, PROC, CYP24A1 | ALDH1A1 3055/4885CYP3A4 1091/4885CYP4F2 124/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | ALDH1A1 1555/4885CYP3A4 2857/4885CYP4F2 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.